Xcout IntelSign inSubscribe

Chiesi Farmaceutici competitors & alternatives

PharmaceuticalsItaly

The 12 closest competitors and alternatives to Chiesi Farmaceutici among pharmaceuticals companies — ranked by similarity to what Chiesi Farmaceutici actually does, not by market-cap band.

12Competitors listed

Subscribe to see Chiesi Farmaceutici’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

About Chiesi Farmaceutici

Chiesi Farmaceutici is a global biopharmaceutical group that researches, develops, and commercializes therapeutic solutions for patients. The company focuses primarily on respiratory health, rare diseases, and specialty care.

Chiesi Farmaceutici at a glance

Chiesi Farmaceutici is a pharmaceuticals company headquartered in Italy. Xcout tracks 5 named people at Chiesi Farmaceutici, including Alessandro Chiesi (Vicepresidente).

Chiesi Farmaceutici leadership

  • Alessandro ChiesiVicepresidente
  • Maria Paola ChiesiPresidente del CdA
  • Anna Bonisoli AlquatiHead of Global External Communications
  • Davide PaterliniGlobal External Communications Sr. Manager
  • Michela LijoiGlobal External Communications Sr. Manager

Recent Chiesi Farmaceutici news

Top 12 Chiesi Farmaceutici competitors

Ranked by semantic similarity — how close each company is to Chiesi Farmaceutici by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.

Pharming Group N.V.PHAR · PharmaceuticalsLeiden, Netherlands
67% matchPublic

Similar pharmaceuticals company

Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Market cap$834.5M
Employees404
Pharming Group N.V. competitors & alternatives →

Analyze another company

Search any company we track to see its competitive set.

Or describe a company

Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.

See the full profile of Chiesi Farmaceutici and its market

Funding, investors, tech stack, hiring signals, leadership and corporate events — for Chiesi Farmaceuticiand every competitor above — in one live dashboard.

Subscribe to Xcout Intel →